a b s t r a c t 3-iodothyroacetic acid (TA 1 ) is among the by-products of thyroid hormone metabolism suspected to mediate the non-genomic effects of the hormone (T3).
Introduction
Among endogenous occurring thyroid hormone (T3) derivatives is 3-iodothyroacetic acid (TA 1 ), produced by alternative metabolism of T3 involving decarboxylases, amine oxidases and deiodinases activities. We demonstrated recently that TA 1, in the central nervous system of mice, can be produced by the oxidative deamination of endogenous but also pharmacologically administered 3-iodothyronamine (T 1 AM) carried on by monoamine oxidases (Laurino et al., 2015a) . This finding suggested that the biosynthetic relationship between TA 1 and T 1 AM might have physio but also pharmacological relevance, implying the two metabolites might reproduce similar effects when administered to rodents. Experimental evidence indicate that it might be not so.
We reported previously that TA 1 pharmacologically administered to mice at low doses induced itch, reduction of noxious heat threshold (Laurino et al., 2015b) and, as T 1 AM, it stimulated memory acquisition and reverted scopolamine-induced amnesia (Musilli et al., 2014) . Interestingly, TA 1 , as T 1 AM, induced these effects showing a wide range of dose effectiveness and inverted Ushaped dose response curves. On the contrary, Hoefig et al. (2015) reported evidence indicating that TA 1 administration, differently from T 1 AM, did not induce hypothermia, bradycardia or modification of feeding behavior.
We believed important to explore further on possible similarities or differences between the pharmacological effects of T 1 AM and TA 1 in order to understand which drug should be used to expect a certain effect. To this aim we investigated whether TA 1 was able to induce, as already reported for T 1 AM (and T3), mice wakefulness (James et al., 2013) and whether TA 1 interacted at GABA-A receptor (GABA-AR) which is among the master regulators of drowsiness, sedation and sleep.
To explore these points we studied the effect of administering 1.32, 4 and 11 mg/kg TA 1 to mice prone to sleep for receiving an ipnotic dose of ethanol while the interaction at GABA-AR was studied electrophysiologically and by binding experiments.; Abbreviations: 3-iodothyroacetic acid (TA 1 ); 3-iodothyroanmine (T 1 AM); 3,3 0 ,5,5 0 -tetra-iodothyroacetic acid (TETRAC); triiodothyroacetic acid (TRIAC), GABA-A receptor, GABA-AR; Thyroid hormone, T3.
Methods

Animals
All animal experiments were carried out in accordance with the U.K. Animals (Scientific Procedures) Act, 1986 and associated guidelines, the European Communities Council Directive of 24 November 1986 (86/609/EEC) or the National Institutes of Health guide for the care and use of Laboratory animals (NIH Publications No. 80-23, revised 1978) . All efforts were made to minimize the number of animals used and their suffering. For this study we received the permission from the Ethical Committee for animal health (#959/2015-PR) from the Italian Ministry of Health.
A total of 80 male mice (CD1 strain; 20e30 g) from ENVIGO (Italy) were used. The animals were kept at 22 ± 1 C with a 12 h lightedark cycle (light on at 07:00 h) and were fed a standard laboratory diet with water ad libitum. Five mice were housed per cage.
Wistar rats 15-to28-day old from Envigo (Italy) were used for preparation of acute hippocampal slices. Rats were sacrificed by decapitation under anesthesia with isoflurane and used for the preparation of acute organotypic hippocampal slices.
All efforts were made to minimize animal suffering, to reduce the number of animals used, and to utilize alternatives to in vivo techniques, if available.
2.2. Ethanol-induced sleep 2.2.1. Experimental setting 1
Mice were pretreated with either saline or TA 1 (1.32, 4 and 11 mg/kg) and, after 10 min, they received an hypnotic dose of ethanol (3.5 g/kg, i.p.).
Experimental setting 2
Mice received a hypnotic dose of ethanol (3.5 g/kg, i.p.) and, after 5 min, they were treated with saline or TA 1 (1.32, 4 and 11 mg/ kg, i.p).
In experimental setting 1, the time of latency for onset of sedation, defined as the inability of mice to right themselves when positioned on their back (LORR latency) and the time to regain it (i.e. the time elapsed between the onset of sedation and the righting of mice back onto all four paws, known as the LORR duration) were recorded. Recovery was defined as the time at which mice could right themselves three times in 30 s after being placed on their backs. In experimental setting 2 only the LORR duration was recorded.
Results are presented as the mean ± SEM of measures from 10 different mice.
Preparation of acute rat hippocampal slices
Brains were removed and mounted in the slicing chamber of a vibroslicer (Leica VT 1000S). Horizontal slices (250 mm in thickness) Mice were treated with saline (Veh) or with 1.32, 4 or 11 mg/kg TA 1 and after 10 min (setting 1) or just after they received ethanol (3.5 g/kg; i.p., setting 2). The time of onset (setting 1) and the duration of sleep (setting 1 and 2) was measured as described in "Methods". Panel A: the effect of TA 1 given before ethanol (pre-TA1) on LORR latency. Panel B: the effect of TA 1 given before ethanol (pre-TA1) on LORR duration. Panel C: the effect of TA1 given after ethanol (post-TA1) setting 2 on LOOR duration. Results are expressed as the means ± SEM of measures relative to 10 mice. *p < 0.05 vs. Veh; **P < 0.01 vs. Veh.
were cut from the hippocampi in chilled artificial cerebral spinal solution (aCSF) saturated with 95% O 2 /5% CO 2 containing 130 mM NaCl, 3.5 mM KCl, 1.25 mM NaH 2 PO 4 , 25 mM NaHCO 3 , 10 mM glucose, 2 mM CaCl 2 and 2 mM MgSO 4 . The slices were allowed to recover in the same solution maintained at 34 C with constant oxygenation for 1 h prior to the experiments.
Solutions
The extracellular solution contained: 140 mM NaCl, 2 mM CaCl 2 , 1 mM MgCl 2 , 3 mM KCl, 10 mM Hepes and 10 mM D(þ) glucose, adjusted to pH 7.3 with NaOH and with an osmolarity of 300e310 mosmol/l. Pipettes were filled with an intracellular solution containing: 140 mM KCl, 10 mM HEPES, 5 mM EGTA, 2 mM MgCl 2 , 5 mM Na2Pcreatine, 0.3 mM NaGTPand 2 mM MgATP adjusted to pH 7.3 with KOH, with an osmolarity of 310-315mosmol/l. The cells were continuously perfused with the extracellular solution using a gravity-fed perfusion system. To isolate the GABA A mediated current, 50 mM APV and 10 mM NBQX was added to the extracellular solution.
Whole-cell recordings
Voltage-clamp recordings were performed with a PC-505B amplifier (Warner, Handen, CT, USA). Signals were sampled at 10 kHz, and low-pass filtered at 1 kHz with a Digidata 1440 A acquisition board and Clampex 10 (Axon, Sunnyvale, CA,USA). Pipettes were pulled from borosilicate capillaries (Harvard Apparatus, London, UK) using a Narishige PP830 vertical puller (Narishige International Ltd, London, UK) and filled with (in mM): K þ Methanesulfonate (120), KCl (15), HEPES (10), EGTA (0,1), MgCl2, (2), Na2PhosphoCreatine (5), Na2GTP (0.3), MgATP (2) resulting in a bath resistance of 3e5 MU. Pipette capacitance transients were cancelled while no whole-cell compensation was used and the cells were held at À60 mV. All recordings were made at 21e23 C. Spontaneous GABAergic benzo[f]quinoxaline-7-sulfonamide disodium salt hydrate (NBQX, 10 mM) and D-2-Amino-5-phosphonovaleric acid (D-APV, 50 mM) and recorded in gap free mode. At the end of recordings, 10 mM bicuculline was applied to confirm the GABAergic nature of synaptic currents.
Binding at benzodiazepine receptors
Crude synaptic membranes were prepared from cerebral cortex of male CD1 mice (30e35 g), according to Zukin and Young, (1974) .
Briefly, cerebral cortex was homogenized in 20 vol of ice cold 0.32 M sucrose in a Potter-Elvehjem homogenizer. The resulting pellet was discarded, and the supernatant was recentrifuged at 30,000g for 20 min at 4 C. Then the pellet was osmotically shocked by suspension in 10 vol of 0.05 M Tris-citrate buffer, pH 7.4 containing protease inhibitors and recentrifuged at 30,000g for 20 min at 4 C. The resulting membranes were frozen and washed for removing endogenous GABA from cerebral cortex (Martini et al., 1983) . Finally, the pellet was suspended in 10 vol of 50 mM Triscitrate buffer, pH 7.4, and used in the binding assay.
[
3 H]Flumazenil binding were performed as previously reported (Bertelli et al., 1998) .
Aliquots of the membrane fractions (0.2e0.3 mg of protein) were incubated at 0 C for 90 min in 0. evaluated. After incubation, the samples were harvested onto glass fiber GF/B filters by means of a harvester and washed with 3 Â 5 mL of ice-cold buffer. The filters were dried and an amount of 4 mL of Filter Count scintillation cocktail (Perkin Elmer LS) was added; radioactivity was counted in a Perkin Elmer TRICARB 1500 liquidphase scintillation b counter.
Statistical analysis
Data are expressed as mean ± SEM of independent experiments. Statistical analysis was performed by one-way ANOVA, followed by post hoc comparison test. The threshold of statistical significance was set at p < 0.05. Data analysis was performed using the GraphPad Prism 5.0 statistical program (GraphPad software, San Diego, CA, USA). Data from electrophysiological recordings were generated with OriginPro 8.1, and statistical significance was assessed with ANOVA followed by Tukey's test. Differences were considered significant for p < 0.05.
Results
TA1, given systemically, reduces LORR duration and increases the LORR latency of ethanol-induced sleep
The effect of TA 1 (1.32, 4 and 11 mg/kg) on the LORR latency and the LORR duration of ethanol-induced sleep was evaluated at two experimental settings.
When administered in the conditions of "Setting 1", One-way analysis of variance indicated that TA 1 significantly affected LOOR latency (P < 0.05 vs. ethanol; F(3,55) ¼ 3.63; h2 ¼ 0.173). Post hoc analysis indicated that only 4 mg/kg TA 1 significantly increased LORR latency (p < 0.05 vs. ethanol).
TA 1 significantly impacted on LOOR duration (P < 0.001; F(3,53) ¼ 7.89; h2 ¼ 0.32) and post hoc analysis (Tukey's Multiple Comparison Test) indicated that 1.32 and 4 mg/kg TA 1 significantly decreased LORR duration in respect to mice treated with ethanol alone (P < 0.01 and P < 0.001 respectively) (Fig. 1, panels A and B) .
At the dose of 11 mg/kg LOOR duration and latency were not different from vehicle treated mice. When tested at the conditions described as "Setting 2", TA 1 did not modify LOOR duration of ethanol-induced sleep at all of the doses tested (Fig. 1, panel C) .
Electrophysiological recordings: TA1 does not interfere with GABA-A-mediated currents
The effect of TA 1 on LORR latency and the duration of ethanolinduced sleep might be due to an antagonistic effect on GABA A channels, which are among the targets of ethanol. To explore this point, we performed electrophysiological recordings of bicucullinesensitive currents in acute hippocampal slices under AMPA and NMDA receptors blockade. 1 mM TA1 did not modify the frequency or the amplitude of spontaneous GABAergic currents (N neurons ¼ 9; 1 neuron/slice for a total of 9 slices from 3 different rats). The application of 20 mM external bicuculline fully abolished GABA A -mediated synaptic currents.
Our results indicated that TA 1 (1 mM) did not modify sIPSC amplitude (upper panel) or frequency (bottom panel) in 5 CA1 pyramidal neurons after 5 and 10 min of application (Fig. 2). 3.3. TA 1 does not interact at the benzodiazepine binding site of GABA-A receptor TA 1 at all the concentrations tested (1, 10 and 100 mM) did not displace [
3 H]flumazenil binding to brain plasma membranes of mice (Fig. 2, panel B) .
Discussion
We here report that, when administered to mice, at doses close to its endogenous levels, TA 1 increases the latency of onset and reduces the duration of the sleep induced by an acute high dose of ethanol. This effect occurs only when TA 1 is given before and not after ethanol. TA 1 effectiveness shows a typical inverted U-shaped dose effects curve and a wide range of dose effectiveness. TA 1 di per se does not interact either at the orthosteric or at the benzodiazepine sites of GABA-AR, thus suggesting the pro-waking effect of TA 1 results from modulation of GABA-AR.
Ethanol, together with benzodiazepines, is a positive allosteric modulator of the GABA-AR. Benzodiazepine and ethanol have different binding sites on GABA-AR and benzodiazepine agonists and antagonists as flumazenil, have several clinical indications including toxicological ones. In fact, benzodiazepine receptor agonists are used to control symptoms of ethanol withdrawal syndrome while benzodiazepine receptor antagonist, as flumazenil is used to wake up patients from benzodiazepine-induced coma. Even if the molecular mechanism responsible for the ipnotic effect of ethanol is not fully characterized, the involvement of GABA-AR and of excitatory neurotransmission is well stated. When administered to mice, at the same doses active on memory and on pain (Musilli et al., 2014; Laurino et al., 2015b) , TA 1 delayed the time of onset and reduces the duration of ethanol-induced sleep, thus increasing the time of mice wakefulness. This effect implies TA 1 central bioavailability following systemic administration of very low doses and likely the involvement of targets undergoing to rapid desensitization (Laurino et al., 2015a) . To note, TA 1 prowaking effect did not occur when the acid was administered after ethanol, when the animals already slept. This difference in TA 1 effectiveness, in respect of the timing of administration, allows to postulate that the waking mechanisms activated by TA 1 cannot be engaged when the sleep is already onset. In few words, TA 1 was unable to wake-up the animals from a deep sleep. The possibility that TA 1 worked as a GABA-AR agonist/antagonist was excluded by our functional evidence obtained from patching GABA-A neurons and by binding experiments. In fact, TA 1 did not modify bicuculline-sensitive currents of neurons and it was unable to displace flumazenil binding from mice brain plasma membranes. Overall both results indicated TA 1 did not interact at the orthosteric or at the benzodiazepine binding site of the GABA-AR. To note, the lack of interaction of TA 1 at GABA-AR marks a difference among the pharmacodynamics features of TA 1 and those of T3 and other thyroacetic acids including tetra-and tri-iodothyroacetic acids (Martin et al., 2004) , thus indicating that a high steric hindrance is pre-requisite for recognition of thyroid hormone metabolites at the GABA-AR.
Instead, among the possible pro-waking mediators which are released during wakefulness, but not during sleep, is histamine, (Vanni-Mercier et al., 2003) . Histamine is a good candidate for explaining the pro-waking effect of TA 1 since i) is part of the network of sleep/waking mediators ii) histaminergic neurons cannot discharge during sleep and iii) it was already described to take part to other pharmacological effects of TA 1 (Musilli et al., 2014; Laurino et al., 2015b) . However, histamine involvement in TA 1 pro-waking effect could be not explored pharmacologically in the present experimental model. In fact, according to Monti et al. (1986) , the pro-waking histamine receptor is the type 1 and histamine type 1 receptor antagonists with central bioavailability induce di per se sedation and favor sleep.
Our results indicate that TA 1 is able to reproduce, when given systemically, the stimulatory effect on wakefulness of T 1 AM or T3 when injected directly in the preoptic area of rat brain (James et al., 2013) . These results add knowledge to the pharmacological profile of TA 1 and suggest that TA 1 may be the active compound responsible for the pro-waking effect of T3 and of T 1 AM.
Conclusions
An increase of vigilance and of attention are pre-requisite to face positively to negative challenges but also to favor learning and memory acquisition. In this context TA 1 works as a potent activator of waking and of learning, two effects which merit to be explored further for their potential clinical usefulness. 
